Shares of Illumina slipped 1.8% in Friday’s pre-market trading despite the gene sequencing company announcing fourth quarter earnings results that beat analysts’ expectations.
Gene sequencing firm Illumina announced today the acquisition of Grail, a company focused on multi-cancer early detection, for $8 billion. Last week, a …
Genetic sequencing company Illumina is in talks to buy Grail for a price tag of more than $8 billion, according to a Bloomberg …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares are up nearly 9% in early trading Tuesday after the embattled pharmaceutical company reported that it will sell assets …
Following market close yesterday, Illumina, Inc. (NASDAQ:ILMN) reported second quarter revenue results of $600.
Illumina, Inc. (NASDAQ:ILMN) announced that its Board of Directors has authorized the company to repurchase, on a discretionary basis, up to $250 million of …
Annoroad and Illumina, Inc. (NASDAQ:ILMN) announced they have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation …
Illumina, Inc. (NASDAQ:ILMN) announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within …
Illumina, Inc. (NASDAQ:ILMN) announced it has named Pensabio, a life science, analytical instruments and diagnostics distributor, headquartered in Sao Paolo, Brazil, as its …
Illumina, Inc. (NASDAQ:ILMN) announced that it will issue results for first quarter 2015 following the close of market on Tuesday, April 21, 2015.
